secwatch.observer — SEC 8-K summary
======================================

Issuer:     RELMADA THERAPEUTICS, INC. (RLMD)
CIK:        0001553643
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001213900-22-071296
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relmada's RELIANCE III MDD trial failed; RELIANCE I results at risk from similar enrollment issues
--------------------------------------------------------------------------------

- RELIANCE III monotherapy trial failed; placebo group mean change of 23 points at one high-enrolling site; 30% of patients from such sites.
- RELIANCE I adjunctive trial results by year-end 2022; 40% of patients from same high-enrolling sites, raising risk of similar failure.
- RELIANCE II adjunctive trial results delayed to 2023; protocol changes being implemented.
- Q3 2022 net loss $39.4M ($1.31/diluted) vs $42.6M ($2.44) prior year; cash $184.2M.
- Company states it has financial flexibility to continue advancing REL-1017.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1553643/000121390022071296/0001213900-22-071296-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1553643/000121390022071296/ea168442-8k_relmada.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-071296

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer